

Human Latent Transforming Growth Factor β 1 (hLatent TGF- β 1)

Orders ■ 877-616-CELL (2355)
orders@cellsignal.com

Support ■ 877-678-TECH (8324)
info@cellsignal.com

Web ■ www.cellsignal.com

rev. 04/10/17


For Research Use Only. Not For Use In Diagnostic Procedures.

Source: Recombinant human latent TGF- β 1 (hLatent TGF- β 1) Leu30-Ser390 (Accession #P01137) was expressed in human 293 cells at Cell Signaling Technology.


Molecular Characterization: Recombinant (hLatent TGF- β 1) contains no "tags" and the nonglycosylated small latent TGF- β 1 complex has a calculated MW of 41,251. DTT-reduced protein migrates as 40 and 13 kDa polypeptides, and the non-reduced cystine-linked homodimers migrate as 80 and 25 kDa proteins. The expected amino-terminal ALDTN of recombinant hTGF- β 1 and the expected amino-terminal LSTSK of recombinant latency-associated peptide (LAP) were verified by amino acid sequencing.

Endotoxin: Less than 0.01 ng endotoxin/1 μ g hLatent TGF- β 1.

Purity: >98% as determined by SDS-PAGE of 6 μ g reduced (+) and non-reduced (-) recombinant hLatent TGF- β 1. All lots are greater than 98% pure




The purity of recombinant hLatent TGF- β 1 was determined by SDS-PAGE of 6 μ g reduced (+) and non-reduced (-) recombinant hLatent TGF- β 1 and staining overnight with Coomassie Blue.



Western blot analysis of extracts from HeLa cells, untreated or treated with the hLatent TGF- β 1 for 25 minutes, using Phospho-Smad2 (Ser465/467) (138D4) Rabbit mAb #3108 (upper) and Smad2 (86F7) Rabbit mAb #3122 (lower).

Bioactivity: The bioactivity of recombinant hLatent TGF- β 1 was determined by assessing inhibition of IL-4 induced HT-2 cell proliferation. The ED₅₀ of each lot is between 4-10 ng/ml and 0.2-0.8 ng/ml after acid activation.



The inhibition of IL-4 induced proliferation in HT-2 cells treated with increasing concentrations of hLatent TGF- β 1 or acid-activated hLatent TGF- β 1 was assessed. After 48 hour treatment with hLatent TGF- β 1, cells were incubated with a chemiluminescent cell viability reagent and the relative light units (RLU) were determined.

Formulation: With carrier: A 0.22 μ m filtered solution of 0.25 mg/ml hLatent TGF- β 1 in PBS, pH 7.2 and 25% (v/v) glycerol containing 20 μ g BSA per 1 μ g hLatent TGF- β 1.

Carrier free: A 0.22 μ m filtered solution of 0.25 mg/ml hLatent TGF- β 1 in PBS, pH 7.2 and 25% (v/v) glycerol.

Storage: Stable at -20°C for 1 year after receipt. *Maintain sterility. Storage at -20°C should be in a manual defrost freezer.*

Applications: Optimal concentration for the desired application should be determined by the user.

Background: Latent TGF- β 1 is a complex of two proteins, latency associated protein (LAP) and TGF- β 1, which is derived from cleavage of a common 75 kDa precursor protein (1). The LAP protein spatially and temporally regulates TGF- β 1 activity by sequestering TGF- β 1 in the extracellular matrix in conjunction with latent TGF- β 1 binding proteins (LTBP)(1). The release of TGF- β 1 is activated by a number of stimuli including proteases, thrombospondin-1, reactive oxygen species, and some integrins (1). Active TGF- β 1 binds to T β RII homodimer, which then complexes with T β RI homodimer (2,3). The oligomeric receptor complex phosphorylates subsets of the Smad proteins that then act to induce or repress a number of target genes (3-5). TGF- β 1 binding can also activate the Erk2, p38, and Jnk pathways via TAK1 (5). Active TGF- β 1 activities include proliferation, angiogenesis, and promotion or inhibition of many immune events (2,4,5). Latent TGF- β 1 is present on the surface of regulatory T cells in association with GARP and may contribute directly to their immunosuppressive activity (6,7).

Background References:

- (1) Annes, J.P. et al. (2003) *J Cell Sci* 116, 217-24.
- (2) Bierie, B. and Moses, H.L. (2006) *Nat Rev Cancer* 6, 506-20.
- (3) Moustakas, A. and Heldin, C.H. (2009) *Development* 136, 3699-714.
- (4) Siegel, P.M. and Massagué, J. (2003) *Nat Rev Cancer* 3, 807-21.
- (5) Tian, M. and Schiemann, W.P. (2009) *Future Oncol* 5, 259-71.
- (6) Tran, D.Q. et al. (2009) *Proc Natl Acad Sci U S A* 106, 13445-50.
- (7) Stockis, J. et al. (2009) *Eur J Immunol* 39, 3315-22.